Skip to content

Estimation of Steatosis on Liver Transplants by Intraoperative Spectrometry

Estimation of Steatosis on Liver Transplants by Intraoperative Spectrometry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05106322
Acronym
iGRAISSE
Enrollment
240
Registered
2021-11-03
Start date
2022-01-14
Completion date
2024-11-14
Last updated
2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplants

Keywords

macrosteatosis, spectrometry, liver transplantation, biopsy, primary non-function

Brief summary

The goal is to have a small spectrometer (pocket size) , reliable and rapid tool that can be used during liver harvesting, which enables macrosteatosis to be evaluated reproducibly and selectively, at any time. This tool must be minimally invasive, inexpensive and without significantly impacting the general organization of multi-organ harvesting. In the operating room, the surgeon will perform an intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta. The surgeon will not be informed of the results of the spectrometer, and will carry out (or not) the biopsy. The spectrometers' results will be compared with definitive histological findings.

Interventions

OTHERintraoperative spectrometer scan

intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Brain-dead donor * Age ≥18 years old * No restriction on the part of the donor or his family regarding the use of the data for research purposes. * No fibrous appearance of the graft (visual assessment), corresponding to a Metavir score ≥ F2

Exclusion criteria

* Living donor * Donor within the Maastricht III criteria (cardiac arrest) * Pre-existing hepatic injury / trauma preventing the intraoperative use of the pocket spectrometer * History of supra-mesocolic surgery or peritonitis leading to perihepatic adhesions (preventing the use of pocket spectrometer) * History of chemotherapy -- Biological cholestasis: * GGT\> 400 IU / L * or total bilirubin ≥ 60micromol / L * or conjugated bilirubin ≥ 30micromol / L

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the concordance between the macrosteatosis quantified by the pocket spectrometer and the macrosteatosis content evaluated by the standard pathological analysisJ0 = intraoperativeAgreement (intra-class correlation coefficient) between the% of macrosteatosis estimated by the pocket spectrometer and that quantified by the pathologist on biopsy (final results only)

Secondary

MeasureTime frameDescription
Assessment of the technical feasibility of using the spectrometer in daily practice, analysis of the causes and incidence of failures (technical or organizational)J0 = intraoperativeNumber of time where the measurement by the pocket spectrometer was successful, ie where it was possible to perform the scans and obtain an estimate of the macrosteatosis, and description of the causes for failure.
Estimation of the concordance between the macrosteatosis values provided by the frozen section analysis, if performed, and the definitive pathology and comparison with the concordance of the pocket spectrometer estimated for the primary objectiveJ0 = intraoperativeAgreement (intra-class correlation coefficient) between the% of macrosteatosis estimated by the pathologist extemporaneously when performed and te one quantified by the pathologist on biopsy (final results only).
Assessment of the concordance between the macrosteatosis visually assessed by the harvesting surgeon and the definitive pathological dataJ0 = intraoperativeAgreement (kappa coefficient) between the% of macrosteatosis macroscopically estimated by the pathologist (in 3 categories: 0-30%, 31-60%,\> 60%) and that quantified by the pathologist on biopsy (final results only )
Evaluation of the spectrometer performance for diagnosis to detect macrosteatosis> 30% and> 60% taking the pathology as a reference standardJ0 = intraoperativeArea under the ROC curve (AUC), sensitivity, specificity, likelihood ratio and predictive values of the spectrometer to detect macrosteatosis\> 30% and\> 60%
Modification and improvement of the current algorithm based on the spectra of the entire cohort in order to assess the gain in spectrometer - anatomopathologyJ0 = intraoperativeAgreement (intra-class correlation coefficient) between the percentage of macrosteatosis estimated by the spectrometer using the second version of the algorithm and the macrosteatosis quantified by pathology
Attempt to create a microsteatosis prediction algorithm (version 3) using data from the global cohortJ0 = intraoperativeAgreement (intra-class correlation coefficient) between the percentage of microsteatosis estimated by the spectrometer and the microsteatosis quantified by the pathology
Evaluation of the potential impact of spectrometer results on the surgeon's decision to accept the graft using simulated resultsJ0 = intraoperativePercentage of acquisitions where the operator would have modified his decision (accept / reject the graft) if the spectrometer estimate had been communicated (scenarios simulated in the questionnaires)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026